IP Library Granted Patent US 11,833,329
Granted Patent B2
US 11,833,329 · App. 17/123,369 · Granted Dec 5, 2023

Techniques for improved automatic drug delivery performance using delivery tendencies from past delivery history and use patterns

Inventors: Joon Bok Lee (Acton, MA); Jason O'Connor (Acton, MA); Yibin Zheng (Hartland, WI)
Assignee: INSULET CORPORATION
A61M5/1723A61M5/14244A61M2005/14208A61M2205/3303A61M2205/3569A61M2205/502A61M2205/52A61M2230/201
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,833,329
App. No.
17/123,369
Granted
Dec 5, 2023
Kind
B2
Abstract

Disclosed are a device, system, methods and computer-readable medium products that provide techniques to implement functionality to receive blood glucose measurements over a period of time. An average of missing blood glucose measurement values may be maintained over a predetermined time period. A count of a number of missing blood glucose measurement values over a period of time may be established. A controller may calculate a divergence of the number of missing blood glucose measurement values over the period of time from the average of missing blood glucose measurements over the predetermined time period. Based on a value of the divergence, a determination that a safety constraint for delivery of insulin is to be reduced. The safety constraint may be reduced by a predetermined percentage. An instruction to deliver an insulin dosage may be generated according to the reduced safety constraint may be forwarded to a wearable drug delivery device.

Claims (48)

1. A system, comprising:

a processor;

a memory storing programming code, an artificial pancreas application, and operable to store data related to the artificial pancreas application, wherein the programming code and the artificial pancreas application are executable by the processor; and

a transceiver operable to receive and transmit signals containing information usable by or generated by the artificial pancreas application,

wherein the processor when executing the artificial pancreas application is operable to control delivery of insulin, and to perform functions, including functions to:

identify a user interaction with a personal diabetes management device;

maintain an average of a number of user interactions with the personal diabetes management device over a predetermined time period;

establish a count of the number of user interactions with the personal diabetes management device over a period of time;

calculate a divergence of the number of user interactions with the personal diabetes management device over the predetermined time period from the average number of user interactions with the personal diabetes management device over the period of time; based on a value of the divergence, reduce a safety constraint; and

generate an instruction to deliver an insulin dosage according to the reduced safety constraint.

2. The system of claim 1 , further comprising:

a personal diabetes management device, including a processor, wherein the personal diabetes management device configured to generate a signal indicating the user interaction with the personal diabetes management device and output the signal for receipt by the transceiver, wherein the personal diabetes management device is communicatively coupled to the transceiver.

3. The system of claim 1 , wherein the user interaction is a user activation of the system to view their current system status.

4. The system of claim 1 , wherein the processor, when reducing the safety constraint is further operable to:

reduce the safety constraint by a predetermined percentage.

5. The system of claim 1 , wherein the safety constraint is one or more of a maximum amount of total daily insulin to be delivered to a user, a limit on a basal rate of insulin to be delivered, a limit based on an insulin-on-board value, or a limit based on a glucose concentration value.

6. The system of claim 1 , wherein the processor, when calculating the divergence, is further configured to:

obtain the count of the number of user interactions per the period of time over the predetermined time period and an average number of user interactions per the predetermined time period; and

use the obtained count of the number of user interactions and the average number of user interactions in a function to calculate the divergence of the number of the user interactions.

7. The system of claim 1 , wherein the processor, when determining whether the safety constraint for delivery of insulin is to be reduced, is configured to:

determine whether the value of the divergence is greater than a predetermined threshold, wherein the predetermined threshold is tuned based on one or more of a user's age, the user's insulin sensitivity or a type of physical activity partaken by the user.

8. The system of claim 1 , further comprises:

a blood glucose sensor communicatively coupled to the processor wherein the blood glucose sensor is operable to:

measure a blood glucose value at a predetermined time interval; and

provide measured blood glucose values to the processor and the artificial pancreas application.

9. The system of claim 1 , further comprises:

a wearable drug delivery device communicatively coupled to the processor, wherein the wearable drug delivery device includes a pump mechanism and a medical device processor, wherein the medical device processor is operable to:

receive the forwarded instruction to deliver the calculated future insulin dosage; and

actuate the pump mechanism in response to the received instruction.

10. The system of claim 1 , wherein the processor is further operable to:

forward the generated instruction to a wearable drug delivery device.

11. A computer readable medium encompassing programming instructions that when executed by a processor cause the processor to:

identify a user interaction with a personal diabetes management device;

maintain an average of a number of user interactions with the personal diabetes management device over a predetermined time period;

establish a count of the number of user interactions with the personal diabetes management device over a period of time;

calculate a divergence of the number of user interactions with the personal diabetes management device over the predetermined time period from the average number of user interactions with the personal diabetes management device over the period of time;

based on a value of the divergence, reduce a safety constraint; and

generate an instruction to deliver an insulin dosage according to the reduced safety constraint.

12. The computer readable medium of claim 11 , wherein the programming instructions, when executed by the processor, further cause the processor to:

forward the generated instruction to a wearable drug delivery device.

13. The computer readable medium of claim 11 , wherein the programming instructions, when causing the processor to reduce the safety constraint, further cause the processor to:

reduce the safety constraint by a predetermined percentage.

14. The computer readable medium of claim 11 , wherein the safety constraint is one or more of: a maximum amount of total daily insulin to be delivered to a user, a limit on a basal rate of insulin to be delivered, a limit based on an insulin-on-board value, or a limit based on a glucose concentration value.

15. The computer readable medium of claim 11 , wherein the programming instructions cause the processor, when calculating the divergence, to:

obtain the count of the number of user interactions per the period of time over the predetermined time period and an average number of user interactions per the predetermined time period; and

use the obtained count of the number of user interactions and the average number of user interactions in a function to calculate the divergence of the number of the user interactions.

16. The computer readable medium of claim 11 , wherein the programming instructions cause the processor, when determining whether the safety constraint for delivery of insulin is to be reduced, to:

determine whether the value of the divergence is greater than a predetermined threshold, wherein the predetermined threshold is tuned based on one or more of a user's age, the user's insulin sensitivity or a type of physical activity partaken by the user.

Assignments (2)
SECURITY AGREEMENT SUPPLEMENT FOR INTELLECTUAL PROPERTY Recorded Nov 16, 2022
From: INSULET CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
Reel/Frame 061951/0977 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 24, 2020
From: ZADE, ASHUTOSH; LEE, JOON BOK; ZHENG, YIBIN; O'CONNOR, JASON
To: INSULET CORPORATION
Reel/Frame 054746/0893 →